Video: Biogen Rises Following Novo's Weight-Loss Drug Setback in Alzheimer's Treatment

Written by Emily J. Thompson, Senior Investment Analyst

BIIB-1.61%

BMY-0.51%

NVO+0.98%

Updated: Nov 24 2025

0mins

YouTube Launch: The Fly has expanded its stock market reporting by launching a YouTube channel.
Market Insights: The channel aims to provide insights on market openings and stock movements.

BIIB

$171.01+Infinity%1D

Analyst Views on BIIB

Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 186.19 USD with a low forecast of 135.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

25 Analyst Rating

11 Buy

13 Hold

1 Sell

Moderate Buy

Current: 173.800

Low

135.00

Averages

186.19

High

250.00

Current: 173.800

Low

135.00

Averages

186.19

High

250.00

Goldman Sachs

Salveen Richter

Buy

maintain

$197 -> $225

2026-01-08

Reason

Goldman Sachs

Salveen Richter

Price Target

$197 -> $225

AI Analysis

2026-01-08

maintain

Buy

Reason

Goldman Sachs analyst Salveen Richter raised the firm's price target on Biogen to $225 from $197 and keeps a Buy rating on the shares. After strong sector performance in 2025 driven by market dynamics, easing policy risks, and improving fundamentals, momentum is expected to continue in 2026 as these factors and their secondary effects, such as M&A, persist, the analyst tells investors in a research note.

Truist

Hold

maintain

$142 -> $190

2026-01-08

Reason

Truist

Price Target

$142 -> $190

2026-01-08

maintain

Hold

Reason

Truist raised the firm's price target on Biogen to $190 from $142 and keeps a Hold rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BIIB

Unlock Now

Mizuho

Outperform

maintain

$177 -> $207

2026-01-08

Reason

Mizuho

Price Target

$177 -> $207

2026-01-08

maintain

Outperform

Reason

Mizuho raised the firm's price target on Biogen to $207 from $177 and keeps an Outperform rating on the shares. The firm updated the company's model, saying 2026 is "looking a bit better" for Biogen.

Mizuho

Outperform

maintain

$177 -> $207

2026-01-07

Reason

Mizuho

Price Target

$177 -> $207

2026-01-07

maintain

Outperform

Reason

Mizuho raised the firm's price target on Biogen to $207 from $177 and keeps an Outperform rating on the shares after slight adjustments to Mizuho's assumptions in the company's pipeline programs. The firm told investors that it continues to watch the Leqembi launch, and multiple clinical catalysts expected in 2026, primarily in the mid/2H26.

About BIIB

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.